KRAS G12V
8
2
5
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
0%
0 trials in Phase 3/4
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (8)
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors
Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma
TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors
CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors
Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
RE001 T Cell Injection for the Treatment of KRAS G12V Mutated Solid Tumors